Progressive liver impairment as a predictor of reduced survival in individuals with EGFR-mutated non-small cell lung cancer and liver metastases undergoing treatment with EGFR tyrosine kinase inhibitors - Top-Institutions - MDSpire

Progressive liver impairment as a predictor of reduced survival in individuals with EGFR-mutated non-small cell lung cancer and liver metastases undergoing treatment with EGFR tyrosine kinase inhibitors

  • By

  • Wen Zhang

  • Xuemei Wu

  • Xiaorong Sun

  • Jian Wen

  • Xiaoli He

  • Mingzhou Zhang

  • Guansong Wang

  • Zhi Xu

  • January 23, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, NY

    Key Differentiators

    • Medical Oncology
    • Thoracic Oncology
    • Hepatology

  • #2

    Dana-Farber Cancer Institute
    Dana-Farber Cancer Institute

    Boston, MA

    Key Differentiators

    • Medical Oncology
    • Thoracic Oncology
    • Hepatology

  • #3

    MD Anderson Cancer Center
    MD Anderson Cancer Center

    Houston, TX

    Key Differentiators

    • Medical Oncology
    • Thoracic Oncology
    • Hepatology

  • #4

    National Cancer Center Hospital
    National Cancer Center Hospital

    Tokyo, Tokyo Prefecture

    Key Differentiators

    • Medical Oncology
    • Thoracic Oncology
    • Hepatology

  • #5

    Xinqiao Hospital, Army Medical University
    Xinqiao Hospital, Army Medical University

    Chongqing, Chongqing

    Key Differentiators

    • Medical Oncology
    • Thoracic Oncology
    • Hepatology

Original Source(s)

Progressive liver impairment as a predictor of reduced survival in individuals with EGFR-mutated non-small cell lung cancer and liver metastases undergoing treatment with EGFR tyrosine kinase inhibitors

  • by Wen Zhang, Xuemei Wu, Xiaorong Sun, Jian Wen, Xiaoli He, Mingzhou Zhang, Guansong Wang, Zhi Xu

  • January 23, 2026

Related Content

Is full adherence mandatory? Real-world outcomes of completing perioperative chemoimmunotherapy in resectable non-small cell lung cancer

Myelodysplastic syndromes complicated by atypical Sweet syndrome: a brief research report

Treatment evolution and survival impact of consolidation therapies in mantle cell lymphoma: insights from an Asia-Pacific real-world registry